Clinical trial
Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic…
NCT00083616 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00083616 |
|---|---|
| Title | Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy |
| Official title | A Phase 2 Multicenter Single Arm Clinical Trial of ABX-EGF Monotherapy in Subjects With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer, Metastatic Cancer |
| Intervention type | Biological |
| Interventions | Panitumumab |
| Enrollment | 185 |
| Start date | Mar 1, 2004 |
| Primary completion | May 1, 2007 |
| Completion | Dec 1, 2008 |
| First posted | May 28, 2004 |
| Last update posted | Jan 10, 2014 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: